Also found in: Dictionary, Thesaurus.
Pharmacologic class: Second-generation cephalosporin
Therapeutic class: Anti-infective
Pregnancy risk category B
Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria.
Exhibits minimal immunosuppressant activity.
Oral suspension: 125 mg/5 ml, 250 mg/5 ml
Powder for injection: 750 mg, 1.5 g, 7.5 g
Premixed containers: 750 mg/50 ml, 1.5 g/50 ml
Tablets: 125 mg, 250 mg, 500 mg
⊘Indications and dosages
➣ Moderate to severe infections, including those of skin, bone, joints, urinary or respiratory tract, gynecologic infections
Adults and children ages 12 and older: 750 mg to 1.5 g I.M. or I.V. q 8 hours for 5 to 10 days or 250 to 500 mg P.O. q 12 hours
Children ages 3 months to 12 years: 50 to 100 mg/kg/day I.V. or I.M. in divided doses q 6 to 8 hours
Adults: 750 mg to 1.5 g I.M. or I.V. as a single dose, or 1.5 g I.M. (750 mg in two separate sites), given with 1 g probenecid P.O.
➣ Bacterial meningitis
Adults and children ages 12 and older: Up to 3 g I.V. or I.M. q 8 hours
Children ages 3 months to 12 years: 200 to 240 mg/kg I.V. daily in divided doses q 6 to 8 hours
➣ Otitis media
Children ages 3 months to 12 years: 15 mg/kg P.O. q 12 hours (oral suspension) for 10 days, or 250 mg (tablets) P.O. q 12 hours for 10 days
➣ Pharyngitis; tonsillitis
Adults and children ages 13 and older: 250 mg P.O. b.i.d. for 10 days
Children ages 3 months to 12 years: 125 mg P.O. q 12 hours for 10 days, or 20 mg/kg/day P.O. in two divided doses for 10 days as oral suspension (maximum 500 mg/day)
• Renal impairment (for injectable formulation)
• Hypersensitivity to cephalosporins or penicillins
• Carnitine deficiency
Use cautiously in:
• renal or hepatic impairment
• pregnant or breastfeeding patients
• Reconstitute drug in vial with sterile water for injection.
• Give by direct I.V. injection over 3 to 5 minutes into large vein or flowing I.V. line.
• For intermittent I.V. infusion, reconstitute drug with 100 ml of dextrose 5% in water or normal saline solution; administer over 15 minutes to 1 hour. For continuous infusion, give in 500 to 1,000 ml of compatible solution; infuse over 6 to 24 hours.
• Inject I.M. doses deep into large muscle mass.
• Give oral form with food.
• Be aware that tablets and oral suspension are exchangeable on a milligram-for-milligram basis.
CNS: headache, hyperactivity, hypertonia, seizures
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, pseudomembranous colitis
GU: hematuria, vaginal candidiasis, renal dysfunction, acute renal failureHematologic: hemolytic anemia, aplastic anemia, hemorrhage
Hepatic: hepatic dysfunction Metabolic: hyperglycemia
Skin: toxic epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome
Other: allergic reaction, drug fever, superinfection, anaphylaxis
Drug-drug.Antacids containing aluminum or magnesium, histamine2-receptor antagonists: increased cefuroxime absorption
Probenecid: decreased excretion and increased blood level of cefuroxime
Drug-diagnostic tests.Blood glucose, Coombs' test, urine glucose tests usingBenedict's solution: false-positive results
Glucose, hematocrit: decreased levels
White blood cells in urine: increased level
Drug-food.Moderate- or high-fat meal: increased drug bioavailability
• Monitor patient for life-threatening adverse effects, including anaphylaxis, Stevens-Johnson syndrome, and pseudomembranous colitis.
• Monitor neurologic status, particularly for signs of impending seizures.
• Monitor kidney and liver function test results and intake and output.
• Monitor CBC with differential and prothrombin time; watch for signs and symptoms of blood dyscrasias.
• Monitor temperature; watch for signs and symptoms of superinfection.
• Advise patient to immediately report rash or bleeding tendency.
• Instruct patient to take drug with food every 12 hours as prescribed.
• Teach patient how to recognize signs and symptoms of superinfection. Instruct him to report these right away.
• Advise patient to report CNS changes.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.